A small molecule approach to engineering vascularized tissue

Biomaterials

Volumn 34, Issue 12, 2013, Pages 3053-3063

  Doorn, Joyce ^a   Fernandes, Hugo A M ^a   Le, Bach Q ^a   van de Peppel, Jeroen ^b   van Leeuwen, Johannes P T M ^b   De Vries, Margreet R ^a,b,c,d   Aref, Zeen ^c   Quax, Paul H A ^c   Myklebost, Ola ^d   Saris, Daniel B F ^a   van Blitterswijk, Clemens A ^a   de Boer, Jan ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Angiogenesis; Cell signaling; Mesenchymal stem cells; Stem cell

Indexed keywords

ANGIOGENESIS; CELL LINES; CELL SIGNALING; CELL TYPES; CYTOKINES; GROWTH FACTOR; HIGH THROUGHPUT SCREENING; IMMUNOMODULATION; IN-PROCESS; IN-VIVO; INTERLEUKIN-8; MESENCHYMAL STEM CELL; MESENCHYMAL STROMAL CELLS; PHENANTHROLINES; PROTEOMICS; SECRETOME; SIGNALING PATHWAYS; SMALL MOLECULES; TISSUE REPAIR; VASCULARIZED TISSUES; VESSEL FORMATION;

ACTIVATION ANALYSIS; BLOOD VESSELS; CELL CULTURE; GENE EXPRESSION; MOLECULAR BIOLOGY; MOLECULES; PHYSIOLOGY; STEM CELLS; TISSUE;

TISSUE ENGINEERING;

INTERLEUKIN 8; PHENANTHROLINE;

ANIMAL EXPERIMENT; ARTICLE; CELL HYPOXIA; CELL IMMORTALIZATION; CELL TYPE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; VASCULARIZATION;

BASE SEQUENCE; BLOOD VESSELS; CELL LINE; DNA PRIMERS; GENE EXPRESSION PROFILING; HUMANS; MESENCHYMAL STROMAL CELLS; SMALL MOLECULE LIBRARIES; TISSUE ENGINEERING;

EID: 84873416452     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.12.037     Document Type: Article

References (66)

1. Haynesworth S.E., Baber M.A., Caplan A.I. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 1996, 166(3):585-592.
2. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. The Lancet 2008, 371(9624):1579-1586.
3. Caplan A.I. Why are MSCs therapeutic? New data: new insight. J Pathol 2009, 217(2):318-324.
4. Baker M. Stem-cell drug fails crucial trials. Nat News 2009.
5. Garcia-Olmo D., Herreros D., Pascual I., Pascual J.A., Del-Valle E., Zorrilla J., et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009, 52:79-86.
6. Menasche P. Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol 2010, 50(2):258-265.
7. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30(1):42-48.
8. Chabannes D., Hill M., Merieau E., Rossignol J., Brion R., Soulillou J.P., et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007, 110(10):3691-3694.
9. Falanga V., Iwamoto S., Chartier M., Yufit T., Butmarc J., Kouttab N., et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007, 13:1299-1312.
10. Orlic D., Kajstura J., Chimenti S., Bodine D.M., Leri A., Anversa P. Bone marrow stem cells regenerate infarcted myocardium. Pediatr Transplant 2003, 7(Suppl. 3):86-88.
11. Quevedo H.C., Hatzistergos K.E., Oskouei B.N., Feigenbaum G.S., Rodriguez J.E., Valdes D., et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A 2009, 106(33):14022-14027.
12. Nagaya N. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005, 112(8):1128-1135.
13. Shabbir A., Zisa D., Suzuki G., Lee T. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol 2009, 296(6):1888-1897.
14. Uemura R., Xu M., Ahmad N., Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006, 98(11):1414-1421.
15. Leiker M., Suzuki G., Iyer V.S., Canty J.M., Lee T. Assessment of a nuclear affinity labeling method for tracking implanted mesenchymal stem cells. Cell Transplant 2008, 17(8):911-922.
16. Crisostomo P., Markel T.A., Wang Y., Meldrum D. Surgically relevant aspects of stem cell paracrine effects. Surgery 2008, 143(5):577-581.
17. Lennon D.P., Edmison J.M., Caplan A.I. Cultivation of rat marrow-derived mesenchymal stem cells in reduced oxygen tension: effects on in vitro and in vivo osteochondrogenesis. J Cell Physiol 2001, 187(3):345-355.
18. Hu X., Yu S.P., Fraser J.L., Lu Z., Ogle M.E., Wang J.-A., et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 2008, 135(4):799-808.
19. Hung S.-C., Pochampally R.R., Chen S.-C., Hsu S.-C., Prockop D.J. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007, 25(9):2363-2370.
20. Hung S.C., Pochampally R.R., Hsu S.C., Sanchez C., Chen S.C., Spees J., et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS ONE 2007, 2(5):e416.
21. Lendahl U., Lee K.L., Yang H., Poellinger L. Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet 2009, 10(12):821-832.
22. Volkmer E., Kallukalam B.C., Maertz J., Otto S., Drosse I., Polzer H., et al. Hypoxic preconditioning of human mesenchymal stem cells overcomes hypoxia-induced inhibition of osteogenic differentiation. Tissue Eng Part A 2010, 16(1):153-164.
23. Harris A.L. Hypoxia a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2(1):38-47.
24. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3(10):721-732.
25. 2-regulated prolyl hydroxylation. Science 2001, 292(5516):468-472.
26. Heath T., Fraley R., Papahdjopoulos D. Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab')2 to vesicle surface. Science 1980, 210(4469):539-541.
27. Leserman L., Barbet J., Kourilsky F., Weinstein J. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 1980, 288(5791):602-604.
28. Leserman L., Machy P., Barbet J. Cell-specific drug transfer from liposomes bearing monoclonal antibodies. Nature 1981, 293(5829):226-228.
29. Chan J.M., Zhang L., Tong R., Ghosh D., Gao W., Liao G., et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A 2010, 107(5):2213-2218.
30. Dhar S., Kolishetti N., Lippard S.J., Farokhzad O.C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A 2011, 108(5):1850-1855.
31. Kolishetti N., Dhar S., Valencia P.M., Lin L.Q., Karnik R., Lippard S.J., et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A 2010, 107(42):17939-17944.
32. Rothenfluh D.A., Bermudez H., O'Neil C.P., Hubbell J.A. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat Mater 2008, 7(3):248-254.
33. Nembrini C., Stano A., Dane K.Y., Ballester M., van der Vlies A.J., Marsland B.J., et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A 2011, 108(44):E989-E997.
34. Service R.F. Nanoparticle trojan horses gallop from the lab into the clinic. Science 2010, 330(6002):314-315.
35. Ganta S., Devalapally H., Shahiwala A., Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 2008, 126(3):187-204.
36. Doorn J., van de Peppel J., van Leeuwen J.P.T.M., Groen N., van Blitterswijk C.A., de Boer J. Pro-osteogenic trophic effects by PKA activation in human mesenchymal stromal cells. Biomaterials 2011, 32(26):6089-6098.
37. Siddappa R., Mulder W., Steeghs I., van de Klundert C., Fernandes H., Liu J., et al. cAMP/PKA signaling inhibits osteogenic differentiation and bone formation in rodent models. Tissue Eng Part A 2009, 15(8):2135-2143.
38. Xia M., Huang R., Sun Y., Semenza G.L., Aldred S.F., Witt K.L., et al. Identification of chemical compounds that induce HIF-1α activity. Toxicol Sci 2009, 112(1):153-163.
39. Chau N.M., Rogers P., Aherne W., Carroll V., Collins I., McDonald E., et al. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Res 2005, 65(11):4918-4928.
40. Fernandes H., Mentink A., Bank R., Stoop R., van Blitterswijk C., de Boer J. Endogenous collagen influences differentiation of human multipotent mesenchymal stromal cells. Tissue Eng Part A 2010, 16(5):1693-1702.
41. O'Brien J., Wilson I., Orton T., Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000, 267(17):5421-5426.
42. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408.
43. Roodhart J.M.L., Daenen L.G.M., Stigter E.C.A., Prins H.-J., Gerrits J., Houthuijzen J.M., et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 2011, 20(3):370-383.
44. Liu J., Barradas A., Fernandes H., Janssen F., Papenburg B., Stamatialis D., et al. In vitro and in vivo bioluminescent imaging of hypoxia in tissue-engineered grafts. Tissue Eng Part C Methods 2010, 16(3):479-485.
45. Wenger R.H. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005, 2005(306):re12.
46. Di Santo S.Y.Z., Wyler von Ballmoos M., Voelzmann J., Diehm N., Baumgartner I., Kalka C. Novel cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned medium can replace progenitor cell transplantation. PLoS ONE 2009, 4(5):e5643.
47. Amin A.H., Abd Elmageed Z.Y., Nair D., Partyka M.I., Kadowitz P.J., Belmadani S., et al. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest 2010, 90(7):985-996.
48. Pola R., Ling L.E., Silver M., Corbley M.J., Kearney M., Blake Pepinsky R., et al. The morphogen Sonic Hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 2001, 7(6):706-711.
49. Kusano K.F., Pola R., Murayama T., Curry C., Kawamoto A., Iwakura A., et al. Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. Nat Med 2005, 11(11):1197-1204.
50. Kelly B.D., Hackett S.F., Hirota K., Oshima Y., Cai Z., Berg-Dixon S., et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003, 93(11):1074-1081.
51. Benita Y., Kikuchi H., Smith A.D., Zhang M.Q., Chung D.C., Xavier R.J. An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 2009, 37(14):4587-4602.
52. Ebert A.D., Svendsen C.N. Human stem cells and drug screening: opportunities and challenges. Nat Rev Drug Discov 2010, 9(5):367-372.
53. Maxwell P., Salnikow K. HIF-1: an oxygen and metal responsive transcription factor. Cancer Biol Ther 2004, 3(1):29-35.
54. Murray A.J. Pharmacological PKA inhibition: all may not be what it seems. Sci Signal 2008, 1(22):re4.
55. Li A., Dubey S., Varney M.L., Dave B.J., Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170(6):3369-3376.
56. Kim K.S., Rajagopal V., Gonsalves C., Johnson C., Kalra V.K. A novel role of hypoxia-inducible factor in cobalt chloride- and hypoxia-mediated expression of IL-8 chemokine in human endothelial cells. J Immunol 2006, 177(10):7211-7224.
57. Galindo M., Santiago B., Alcami J., Rivero M., Martín-Serrano J., Pablos J.L. Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. Clin Exp Immunol 2001, 123(1):36-41.
58. Karashima T., Sweeney P., Kamat A., Huang S., Kim S.J., Bar-Eli M., et al. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 2003, 9(7):2786-2797.
59. Chan D.A., Kawahara T.L.A., Sutphin P.D., Chang H.Y., Chi J.-T., Giaccia A.J. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell. 2009, 15(6):527-538.
60. Ruas J.L., Berchner-Pfannschmidt U., Malik S., Gradin K., Fandrey J., Roeder R.G., et al. Complex regulation of the transactivation function of hypoxia-inducible factor-1 alpha by direct interaction with two distinct domains of the CREB-binding protein/p300. J Biol Chem 2010, 285(4):2601-2609.
61. Hechtman D., Cybulsky M., Fuchs H., Baker J., Gimbrone M. Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol 1991, 147(3):883-892.
62. Henkels K.M., Frondorf K., Gonzalez-Mejia M.E., Doseff A.L., Gomez-Cambronero J. IL-8-induced neutrophil chemotaxis is mediated by Janus kinase 3 (JAK3). FEBS Lett 2011, 585(1):159-166.
63. Navarro M., Pu F., Hunt J.A. The significance of the host inflammatory response on the therapeutic efficacy of cell therapies utilising human adult stem cells. Exp Cell Res 2012, 318(4):361-370.
64. Ranganath S.H., Levy O., Inamdar M.S., Karp J.M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 2012, 10(3):244-258.
65. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141(1):52-67.
66. Shibata T., Akiyama N., Noda M., Sasai K., Hiraoka M. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol 1998, 42(4):913-916.